


# UPDATED DATA FROM THE OBSERVATIONAL GIOTAG STUDY PROVIDES INTERIM SURVIVAL DATA\*

Updated data from real-world study shows encouraging overall survival (OS) and time on treatment (ToT) in patients with EGFR T790M-positive NSCLC, especially in patients with Del19-positive tumors

**afatinib** followed by **osimertinib**



*This analysis is the first of a two-step process which assessed updated data from a sub-set of patients with available electronic health records (from the U.S.). A further analysis is planned for early 2020 which will include updated data from Asian and European countries*

## Two-year OS rate

82% in patients with the del19 mutation with acquired T790M

80% in patients with common mutations with acquired T790M



The GioTag population reflects real-world clinical practice and included patients with **ECOG PS  $\geq 2$  (15.3%)** and those with **brain metastases (10.3%)**

\*Reference: MJ Hochmair et al. Overall survival in patients with EGFR mutation-positive NSCLC receiving sequential afatinib and osimertinib: updated analysis of the observational GioTag study. Future Oncol. (2019)

\*\*73.5% of patients had a Del19 mutation, and 26.5% a L858R mutation

The GioTag study is a real-world retrospective, observational and unblinded study with 203 patients

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.